Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ROR1 Is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells.
Ghaderi A, Daneshmanesh AH, Moshfegh A, Kokhaei P, Vågberg J, Schultz J, Olin T, Harrysson S, Smedby KE, Drakos E, Rassidakis GZ, Österborg A, Hojjat-Farsangi M, Mellstedt H. Ghaderi A, et al. Among authors: olin t. Biomedicines. 2020 Jun 23;8(6):170. doi: 10.3390/biomedicines8060170. Biomedicines. 2020. PMID: 32586008 Free PMC article.
First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells.
Hojjat-Farsangi M, Daneshmanesh AH, Khan AS, Shetye J, Mozaffari F, Kharaziha P, Rathje LS, Kokhaei P, Hansson L, Vågberg J, Byström S, Olsson E, Löfberg C, Norström C, Schultz J, Norin M, Olin T, Österborg A, Mellstedt H, Moshfegh A. Hojjat-Farsangi M, et al. Among authors: olin t. Leukemia. 2018 Oct;32(10):2291-2295. doi: 10.1038/s41375-018-0113-1. Epub 2018 Mar 27. Leukemia. 2018. PMID: 29725030 Free PMC article. No abstract available.
A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib.
Daneshmanesh AH, Hojjat-Farsangi M, Ghaderi A, Moshfegh A, Hansson L, Schultz J, Vågberg J, Byström S, Olsson E, Olin T, Österborg A, Mellstedt H. Daneshmanesh AH, et al. Among authors: olin t. PLoS One. 2018 Jun 1;13(6):e0198038. doi: 10.1371/journal.pone.0198038. eCollection 2018. PLoS One. 2018. PMID: 29856777 Free PMC article.
Targeting PFKFB3 radiosensitizes cancer cells and suppresses homologous recombination.
Gustafsson NMS, Färnegårdh K, Bonagas N, Ninou AH, Groth P, Wiita E, Jönsson M, Hallberg K, Lehto J, Pennisi R, Martinsson J, Norström C, Hollers J, Schultz J, Andersson M, Markova N, Marttila P, Kim B, Norin M, Olin T, Helleday T. Gustafsson NMS, et al. Among authors: olin t. Nat Commun. 2018 Sep 24;9(1):3872. doi: 10.1038/s41467-018-06287-x. Nat Commun. 2018. PMID: 30250201 Free PMC article.
Targeting the Receptor Tyrosine Kinase ROR1 by Small Molecules.
Hojjat-Farsangi M, Moshfegh A, Schultz J, Norin M, Olin T, Österborg A, Mellstedt H. Hojjat-Farsangi M, et al. Among authors: olin t. Handb Exp Pharmacol. 2021;269:75-99. doi: 10.1007/164_2021_535. Handb Exp Pharmacol. 2021. PMID: 34490515
A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells.
Ghaderi A, Okhovat MA, Lehto J, De Petris L, Manouchehri Doulabi E, Kokhaei P, Zhong W, Rassidakis GZ, Drakos E, Moshfegh A, Schultz J, Olin T, Österborg A, Mellstedt H, Hojjat-Farsangi M. Ghaderi A, et al. Among authors: olin t. Pharmaceutics. 2023 Apr 5;15(4):1148. doi: 10.3390/pharmaceutics15041148. Pharmaceutics. 2023. PMID: 37111634 Free PMC article.
143 results